We are Neobe
Why immunotherapy fails in solid tumours
01 - Our mission
The barrier
In a subset of patients, a highly fibrotic stroma wraps the tumour. Immune cells and antibodies circulate but cannot cross it. The tumour is immune excluded, and immunotherapy has nothing to work with.
02 - Our mission
The trojan horse
Engineered live biotherapeutics colonise the tumour and express their payload only there. Safe therapeutic bacterial strains with demonstrated tumour colonising properties do the delivery, so the activity stays where the disease is.
03 - Our mission
Immune access
With the barrier remodelled, the tumour surface is exposed. Immune cells reach it, and existing immunotherapies gain a target they could not previously see.
Outcome
Expanding the benefits of immunotherapy to non-responding patients
Programmable live therapeutics, engineered to remove the barriers to immune infiltration in a safe and targeted way.
See the technology
01 - Who are Neobe
We are building a synthetic biology platform to design programmable microbial trojan horses engineered to disrupt the microenvironment of solid tumours, enabling immunotherapy success in patients with immune excluded tumours.
02 - Team
Meet the dedicated team of scientists behind our research
Neobe's leadership has decades of combined experience in cancer biology, advanced therapies and bacterial engineering, supported by recognized leaders in oncology business development. Our world class R&D team is committed to a culture of collaboration and inclusion, working together to bring our engineered LBPs to the clinic.
Meet the team03 - Pipeline
Two differentiated programmes, with demonstrated pre-clinical efficacy
Two proprietary products aimed at enabling immunotherapy efficacy in patients with colorectal, pancreatic and breast cancer - solid cancer indications of high unmet clinical need.
Programme 01
- Colorectal
- Pancreatic
- Breast
- Discovery
- Pre-clinical
- IND-enabling
- Clinical
At IND-enabling studies
Programme 02
- Colorectal
- Pancreatic
- Breast
- Discovery
- Pre-clinical
- IND-enabling
- Clinical
Demonstrated pre-clinical efficacy
04 - News
Read our latest press releases
- Press release
Neobe Therapeutics selected to join CPI-led Biomanufacturing & Pharma SME Delegation to India
Read - Press release
Deeptech from scratch podcast - Pedro Correa de Sampaio
Read - Press release
Neobe selected to present at the first Cambridge x London Life Sciences Showcase during JP Morgan week
Read
05 - Get in touch
Enabling immunotherapy where it does not yet work
For partnering, investment, scientific collaboration or a role on the team, we would like to hear from you.